文献速递肾小球疾病

CCR2介导局灶节段性肾小球硬化中的肾小球损伤及间质纤维化

C-C chemokine receptor type 2 mediates glomerular injury and interstitial fibrosis in focal segmental glomerulosclerosis.
PubMed 文献 · Nephrol Dial Transplant · 2020-01-01

该研究探讨CCR2在原发性局灶节段性肾小球硬化(FSGS)中的作用,发现人FSGS肾小球中CCR2及其配体CCL2表达显著增加;在阿霉素诱导的FSGS小鼠模型中,Ccr2缺陷可减轻肾小球损伤、炎症细胞浸润及纤维化,提示靶向CCR2可能成为FSGS治疗新策略。

要点

  • 人FSGS肾小球中CCR2和CCL2表达显著增加。
  • Ccr2缺陷减轻阿霉素肾病小鼠的肾小球损伤和间质纤维化。
  • 靶向CCR2可能为FSGS提供新的治疗途径。

核心结论

  • CCR2是FSGS中肾小球损伤和疾病进展的重要介质,靶向CCR2可能成为FSGS的新型治疗策略。

研究设计与样本

  • 分析了人FSGS肾小球中CCR2和CCL2的表达,并在体外刺激小鼠肾小球和肾小球细胞检测CCL2表达。
  • 在BALB/c野生型和Ccr2缺陷小鼠中诱导阿霉素肾病(FSGS小鼠模型)以探究CCR2的促炎和促纤维化功能。

主要发现

  • 人FSGS肾小球中CCR2和CCL2表达显著增加。
  • 阿霉素诱导的FSGS中,肾小球CCL2表达增加,伴随进行性肾小球硬化和肾小球nephrin表达降低。
  • 阿霉素刺激离体肾小球和系膜细胞分泌CCL2和TNF,刺激壁层上皮细胞分泌CCL2;TNF可诱导所有肾小球细胞群表达CCL2,以足细胞最显著。
  • Ccr2缺陷的阿霉素肾病小鼠肾小球和肾小管间质中损伤、巨噬细胞和纤维细胞浸润及炎症均减轻,肾小球硬化和肾小管间质纤维化显著改善。

临床怎么用

  • CCR2可作为FSGS治疗的新靶点,未来可探索CCR2靶向治疗在FSGS患者中的应用。

局限性

  • 研究主要基于阿霉素诱导的小鼠模型,尚需进一步临床研究验证CCR2靶向治疗在FSGS患者中的有效性和安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glomerulosclerosis and tubulointerstitial fibrosis are hallmarks of chronic kidney injury leading to end-stage renal disease. Inflammatory mechanisms contribute to glomerular and interstitial scarring, including chemokine-mediated recruitment of leucocytes. In particular, accumulation of C-C chemokine receptor type 2 (CCR2)-expressing macrophages promotes renal injury and fibrotic remodelling in diseases like glomerulonephritis and diabetic nephropathy. The functional role of CCR2 in the initiation and progression of primary glomerulosclerosis induced by podocyte injury remains to be characterized. METHODS: We analysed glomerular expression of CCR2 and its chemokine ligand C-C motif chemokine ligand 2 (CCL2) in human focal segmental glomerulosclerosis (FSGS). Additionally, CCL2 expression was determined in stimulated murine glomeruli and glomerular cells in vitro. To explore pro-inflammatory and profibrotic functions of CCR2 we induced adriamycin nephropathy, a murine model of FSGS, in BALB/c wild-type and Ccr2-deficient mice. RESULTS: Glomerular expression of CCR2 and CCL2 significantly increased in human FSGS. In adriamycin-induced FSGS, progressive glomerular scarring and reduced glomerular nephrin expression was paralleled by induced glomerular expression of CCL2. Adriamycin exposure stimulated secretion of CCL2 and tumour necrosis factor-α (TNF) in isolated glomeruli and mesangial cells and CCL2 in parietal epithelial cells. In addition, TNF induced CCL2 expression in all glomerular cell populations, most prominently in podocytes. In vivo, Ccr2-deficient mice with adriamycin nephropathy showed reduced injury, macrophage and fibrocyte infiltration and inflammation in glomeruli and the tubulointerstitium. Importantly, glomerulosclerosis and tubulointerstitial fibrosis were significantly ameliorated. CONCLUSIONS: Our data indicate that CCR2 is an important mediator of glomerular injury and progression of FSGS. CCR2- targeting therapies may represent a novel approach for its treatment.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Wilkening A, Krappe J, Mühe AM, et al. C-C chemokine receptor type 2 mediates glomerular injury and interstitial fibrosis in focal segmental glomerulosclerosis. Nephrol Dial Transplant. 2020. PMID: 30597038. doi:10.1093/ndt/gfy380

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。